Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Phase 2

Completed

• Conditions: Non-small-cell Lung Cancer
• Interventions: Drug: Gefitinib

• Registration Number: NCT01833572
• Lead Sponsor: Fudan University

Brief Summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1001. This is an open-label, single-arm, phase II interventional clinical trial. The investigators hypothesize that the application of EGFR-TKI, like gefitinib will be efficient and safe in a neo-adjuvant setting. 42 resectable stage II-IIIa NSCLC patients with EGFR activating (19/21) mutations will be eligible to be enrolled. EGFR mutation will be prospectively tested in all the participants' biopsy samples and confirmed in surgical resected samples. Eligible patients will be given gefitinib 250mg for 42days followed with surgical resection of tumor. Efficacy of preoperative gefitinib is based on radiographic (CT response/ORR), pathologic (pathologic response), surgical (complete resection) evaluations, and safety is based on adverse effect evaluations.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-04-11
• Study First Submitted QC: 2013-04-14
• Study First Posted: 2013-04-17
• Study Start: 2013-05
• Primary Completion: 2015-10
• Study Completion: 2015-10
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-11
• Last Update Posted: 2023-07-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

1. Provision of informed consent
2. Pathologically confirmed non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858 mutation.
3. Clinically or pathologically confirmed stage II-IIIA
4. Tolerable to complete resection of lung cancer
5. Male or female aged 18 years and over
6. Able to comply with the required protocol and follow-up procedures, and able to receive oral medications
7. ECOG performance status 0-1.
8. Life expectancy ≥12 weeks.
9. Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level).
10. Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Aspartate amino transferase (AST) and alanine amino transferase (ALT) ≤ 2.5 x upper limit of normal (ULN).
11. Adequate renal function: Serum creatinine ≤ 1.5 x upper limit of normal (ULN), and creatinine clearance≥ 60 ml/min.
12. Measurable disease according to the preset criteria .

Read More

Exclusion Criteria

1. Known severe hypersensitivity to gefitinib or any of the excipients of this product
2. Any serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study
3. Interstitial lung disease(ILD) or pulmonary fibrosis; impaired pulmonary function (e.g. FEV1 <40% predicted value, artery blood gas PaO2<60mmHg)
4. Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).
5. Patients with prior exposure to chemotherapy, irradiation or systemic anti-cancer therapy (e.g. monoclonal antibody therapy) for lung cancer.
6. Previous or current malignancies of other histologies within the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free survival of 5 years; cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix.
7. Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within six months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
8. Eye inflammation or eye infection not fully treated or predisposing factor of this.
9. Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the subject at high risk for treatment-related complications.
10. Patient who has serious active infection
11. Patients who harbouring exon 20 T790M mutation.
12. Pregnancy or breast feeding.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Gefitinib	Gefitinib	A total of 42 cases of resectable stage II-IIIA NSCLCs patients with EGFR activating mutations will be enrolled in this arm.Gefitinib 250 mg/day oral daily is given to patients after enrolment for 42 days or until disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Objective response rate (ORR)	at day 42 of gefitinib treatment

Secondary Outcome Measures

Name	Time	Method
Pathologic response rate	Pathologic response rate is depended on the pathology dignosis after surgery, an expected average of 8 weeks from enrollment.
Complete resection rate	Complete resection rate is depended on the pathology dignosis after surgery, an expected average of 8 weeks from enrollment.
Overall survival (OS)	Participants after surgery will receive long-term follow-up for up to 5 years
Number of participants with adverse events	During the neoadjuvant and perioperative period, an expected average of 10 weeks from enrollment
Quality of life (QoL)	During the neoadjuvant period, an expected average of 6 weeks from enrollment
Disease free survival (DFS)	Participants after surgery will receive long-term follow-up for up to 5 years

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, China